

House Bill 1326

By: Representatives Stephens of the 164th, Jasperse of the 11th, Hawkins of the 27th, and Cooper of the 45th

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to provide for certain provisions relating to Schedule I controlled
3 substances, Schedule III controlled substances, and Schedule IV controlled substances; to
4 provide for certain provisions relating to the definition of dangerous drugs; to provide for
5 related matters; to provide for an effective date; to repeal conflicting laws; and for other
6 purposes.

7 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

8 **SECTION 1.**

9 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
10 substances, is amended in Code Section 16-13-25, relating to Schedule I controlled
11 substances, by revising division (12)(L)(iii) as follows:

12 "(iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl,
13 cyclohexyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom
14 in a cyclic structure;"

15 **SECTION 2.**

16 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
17 substances, by revising subparagraph (E) of paragraph (16) as follows:

18 "(E) By substitution at the 5-position or 6-position with a nitro group or primary
19 amine.;"

20 **SECTION 3.**

21 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
22 substances, by adding new paragraphs to read as follows:

23 "(17) Clonazolam;

24 (18) Cumyl-pegaclone;

25 (19) Diclazepam;

26 (20) Etizolam;

27 (21) Flualprazolam;

28 (22) Flubromazolam."

29 **SECTION 4.**

30 Said chapter is further amended in Code Section 16-13-27, relating to Schedule III controlled
31 substances, by revising subparagraph (D) of paragraph (6) as follows:

32 "(D) ~~Dehydrochlormethyltestosterone~~ Dehydrochloromethyltestosterone;"

33 **SECTION 5.**

34 Said chapter is further amended in paragraph (6) of Code Section 16-13-27, relating to
35 Schedule III controlled substances, by redesignating subparagraph (A) as subparagraph (A.1)
36 and by adding new subparagraphs to read as follows:

37 "(A.01) Androstanedione;

38 (A.05) Androstenediol;

- 39 (A.075) Androstenedione;
40 (A.08) Bolandiol;
41 (A.085) Bolandione;"
42 "(A.75) Bromoandrostanedione;
43 (A.85) Chloromethylandrostenediol;"
44 "(I.25) Furazabol;
45 (I.3) Furuza;
46 (I.5) Halodrol;
47 (I.75) Hemapolin;
48 (I.8) Mestanolone;
49 (I.85) Mestanolone oxime;"
50 "(O.25) Methylandrostanol;
51 (O.5) Methylclostebol;
52 (O.7) Methyldienolone;
53 (O.75) Methylhydroxynandrolone;"
54 "(P.5) Methyltrienolone;"
55 "(R.5) Norbolethone;
56 (R.75) Norclostebol;"
57 "(S.5) Oxabolone;"
58 "(T.5) Oxyguno;"
59 "(Z.5) Tetrahydrogestrinone;"
60 "(AA.5) Trendione;"
61 "(CC) 5alpha-androstan-3,6,17-trione;
62 (DD) 6-bromo-androsta-1,4-diene-3,17-dione;
63 (EE) Delta1-dihydrotestosterone;
64 (FF) 3beta,17beta-dihydroxy-5alpha-androstane;
65 (GG) 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one;

- 66 (HH) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
 67 (II) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
 68 (JJ) 4-hydroxy-androst-4-ene-3,17-dione;
 69 (KK) 17beta-hydroxy-androstano[2,3-d]isoxazole;
 70 (LL) 4,17beta-dihydroxy-androst-4-en-3-one (4-hydroxytestosterone);
 71 (MM) 17alpha-methyl-androsta-1,4-diene-3,17beta-diol;
 72 (NN) 6alpha-methyl-androst-4-ene-3,17-dione;
 73 (OO) 17alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane;
 74 (PP) [3,2-c]pyrazole-androst-4-en-17beta-ol;"

75 **SECTION 6.**

76 Said chapter is further amended in subsection (a) of Code Section 16-13-28, relating to
 77 Schedule IV controlled substances, by repealing paragraph (13.5) in its entirety and by
 78 revising paragraph (34) and adding a new paragraph to read as follows:

- 79 "(34) Zopiclone (including its salts, isomers, and salts of isomers);
 80 (35) Zuranolone."

81 **SECTION 7.**

82 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
 83 defined, by revising paragraphs (556), (654), and (743) of subsection (b) as follows:

- 84 "(556) Meningococcal ~~polysaccharide~~ vaccine;"
 85 "(654) Norgestrel — See exceptions;"
 86 "(743) Pneumococcal ~~polyvalent~~ vaccine;"

87 **SECTION 8.**

88 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
 89 defined, by adding new paragraphs to subsection (b) to read as follows:

- 90 "(13.54) Adamts13, recombinant-krhn;"
91 "(57.5) Anthrax Vaccine Adsorbed, Adjuvanted;"
92 "(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;"
93 "(69.02) Avacincaptad pegol;"
94 "(91.72) Berdazimer;"
95 (91.73) Beremagene geperpavec-svdt;"
96 "(98.4) Bimekizumab;"
97 "(99.5) Birch triterpenes;"
98 "(132.6) Capiwasertib;"
99 "(160.5) Chikungunya Vaccine, Live;"
100 "(194.2) Cipaglucoasidase alfa-atga;"
101 "(206.7) Coagulation Factor X, (human);"
102 "(239.7) Daprodustat;"
103 "(244.45) Delandistrogene moxeparovec-rokl;"
104 "(247.4) Dengue Tetraivalent Vaccine, Live;"
105 "(316.7) Donislecel-jujn;"
106 "(325.465) Durlobactam;"
107 "(328.3) Ebola Zaire Vaccine, Live;"
108 "(331.033) Efbemalenograstim alfa-vuxw;"
109 "(331.0502) Elacestrant;"
110 "(331.0535) Elecsys HIV Duo;"
111 (331.0536) Elecsys HTLV-I/II;"
112 "(331.0595) Elranatamab-bcmm;"
113 "(332.875) Epcoritamab-bysp;"
114 "(334.42) Eplontersen;"
115 "(379.4) Etrasimod;"
116 "(381.24) Fecal microbiota spores, live-brpk;"

- 117 "(383.7) Fezolinetant;"
118 "(388.7) Flotufolastat F 18;"
119 "(406.97) Fruquintinib;"
120 "(414.3) Gepirone;"
121 "(415.6) Glofitamab-gxbm;"
122 "(446.2) Human Papillomavirus 9-valent Vaccine, Recombinant;"
123 "(491.55) Iptacopan;"
124 "(513.72) Leniolisib;"
125 "(529.98) Lotilaner;"
126 "(619.2) Mirikizumab-mrkz;"
127 "(623.2) Momelotinib;"
128 "(625.07) Motixafortide;"
129 "(638.6) Nedosiran;"
130 "(644.63) Nirmatrelvir;
131 (644.64) Nirogacestat;
132 (644.65) Nirsevimab-alip;"
133 "(663.365) Omaveloxolone;"
134 "(663.57) Omidubicel-only;"
135 "(681.6) Palovarotene;"
136 "(692.518) Pegunigalsidase alfa-iwxj;"
137 "(703.63) Perfluorohexyloctane;"
138 "(740.3) Pirtobrutinib;"
139 "(768.3) Pozelimab-bbfg;"
140 "(801.5) Prothrombin complex concentrate, human-lans;"
141 "(822.4) Quizartinib;"
142 "(832.98) Repotrectinib;"
143 "(836.1) Respiratory Syncytial Virus Vaccine;"

144 "(836.4) Retifanlimab-dlwr;"
145 "(836.8) Rezafungin;"
146 "(843.4) Ritlecitinib;"
147 "(846.3) Rozanolixizumab-noli;"
148 "(881.5) Somatrogon-ghla;"
149 "(883.3) Sotagliflozin;"
150 "(883.9) Sparsentan;"
151 "(903.18) Sulbactam;"
152 "(930.99) Talquetamab-tgvs;"
153 "(931.203) Taurolidine;"
154 "(969.9) Tofersen;"
155 "(973.45) Toripalimab-tpzi;"
156 "(1003.3) Trofinetide;"
157 "(1022.5) Valoctocogene roxaparvovec-rvox;"
158 "(1024.8) Vamorolone;"
159 "(1025.8) Varicella Virus Vaccine Live;"
160 "(1027.4) Velmanase alfa-tycv;"
161 "(1042.045) Zavegepant;"
162 "(1042.6) Zilucoplan;"
163 "(1042.95) Zoster Vaccine Recombinant, Adjuvanted;"

164 **SECTION 9.**

165 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
166 defined, by adding a new subparagraph to paragraph (59) of subsection (b) to read as follows:

167 "(BB.5) House Dust Mite Allergen Extract;"

168

SECTION 10.

169 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
170 defined, by revising paragraph (14.25) of subsection (c) as follows:

171 "(14.25) Naloxone — shall also be exempt from subsections (a) and (b) of this Code
172 section when used for drug overdose prevention ~~and when supplied by a dispenser or~~
173 ~~licensed distributor or wholesaler~~ as follows:

174 (A) Nasal adaptor rescue kits containing a minimum of two prefilled 2 ml. luer-lock
175 syringes with each containing 1 mg./ml. of naloxone;

176 (B) Prepackaged nasal spray rescue kits containing single-use spray devices with each
177 containing a minimum of 4 mg./0.1 ml. of naloxone;

178 (C) Muscle rescue kits containing a 10 ml. multidose fliptop vial or two 1 ml. vials with
179 a strength of 0.4 mg./ml. of naloxone when supplied by a dispenser or licensed
180 distributor or wholesaler; or

181 (D) Prepackaged kits of two muscle autoinjectors with each containing a minimum of
182 0.4 mg./ml. of naloxone when supplied by a dispenser or licensed distributor or
183 wholesaler;"

184

SECTION 11.

185 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
186 defined, by adding a new paragraph to subsection (c) to read as follows:

187 "(16.83) Norgestrel — 0.075 mg. tablet when used for the prevention of pregnancy;"

188

SECTION 12.

189 This Act shall become effective upon its approval by the Governor or upon its becoming law
190 without such approval.

191

SECTION 13.

192 All laws and parts of laws in conflict with this Act are repealed.